SmithKline Nicorette second quarter U.S. sales up 9%, but NicoDerm CQ sales fall 18%.
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE NICORETTE SECOND QUARTER SALES INCREASE 9% in the U.S., while sales for NicoDerm CQ fell 18% during the period, SmithKline Beecham said July 21. Helped by the Nicorette nicotine gum increase, the company maintained its 94.4% share of the U.S. OTC smoking cessation market for the quarter. However, U.S. sales for SmithKline's OTC drug products decreased 1% to $517 mil. for the same period.